Ilene R. Baylinson Sells 14,500 Shares of Maximus, Inc. (NYSE:MMS) Stock

Maximus, Inc. (NYSE:MMS) insider Ilene R. Baylinson sold 14,500 shares of the firm’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $68.14, for a total value of $988,030.00. Following the completion of the sale, the insider now owns 2,512 shares in the company, valued at approximately $171,167.68. This represents a 85.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Maximus Stock Down 1.2 %

MMS opened at $65.95 on Friday. The business’s 50-day simple moving average is $73.79 and its 200-day simple moving average is $81.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.72 and a current ratio of 1.72. Maximus, Inc. has a one year low of $64.53 and a one year high of $93.97. The stock has a market capitalization of $3.73 billion, a P/E ratio of 14.18 and a beta of 0.72.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, February 6th. The health services provider reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.22. Maximus had a return on equity of 21.95% and a net margin of 5.28%. Analysts anticipate that Maximus, Inc. will post 6.15 EPS for the current year.

Maximus Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Stockholders of record on Saturday, February 15th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.82%. The ex-dividend date is Friday, February 14th. Maximus’s dividend payout ratio (DPR) is currently 25.81%.

Analyst Upgrades and Downgrades

MMS has been the topic of a number of analyst reports. StockNews.com cut Maximus from a “buy” rating to a “hold” rating in a research note on Friday, February 14th. Raymond James upgraded Maximus from a “market perform” rating to an “outperform” rating and set a $90.00 target price on the stock in a research report on Thursday, January 2nd.

Hedge Funds Weigh In On Maximus

Several institutional investors have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp increased its position in Maximus by 2.0% in the 4th quarter. Mackenzie Financial Corp now owns 2,782,150 shares of the health services provider’s stock valued at $207,687,000 after acquiring an additional 55,583 shares during the period. PharVision Advisers LLC acquired a new position in Maximus in the 4th quarter valued at about $252,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Maximus by 35.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 168,936 shares of the health services provider’s stock valued at $12,611,000 after acquiring an additional 44,182 shares during the period. Voloridge Investment Management LLC increased its position in Maximus by 306.8% in the 4th quarter. Voloridge Investment Management LLC now owns 376,055 shares of the health services provider’s stock valued at $28,073,000 after acquiring an additional 283,608 shares during the period. Finally, Vident Advisory LLC acquired a new position in Maximus in the 4th quarter valued at about $1,075,000. Institutional investors and hedge funds own 97.21% of the company’s stock.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.